Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Mark S. Sulkowski, MD (he/him/his)

Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD, United States

Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Chief of the Division of Infectious Diseases at the Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases in the Department of Medicine and is the Senior Associate Dean for Research for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine.

Prof. Sulkowski has been the principal investigator for more than 150 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded ACTG where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017).

Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018, 2019, 2020, and 2021 he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.

Disclosure(s): AbbVie: Advisor/Consultant (); Aligos Therapeutics: Advisor/Consultant (); Gilead: Advisor/Consultant (); GSK: Advisor/Consultant (), Grant/Research Support (); Janssen: Grant/Research Support (); Precision Biosciences: Advisor/Consultant (); Vir: Grant/Research Support (); Virion: Advisor/Consultant ()

Presentation(s):